Top

Internal and Emergency Medicine

Published in:

01-08-2020 | Losartan | CE - LETTER TO THE EDITOR

Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19

Authors: Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, Andrea Filipponi, Francesco Spannella

Published in: Internal and Emergency Medicine | Issue 5/2020

Excerpt

Dear Editor, …

Spannella F et al (2018) Renin-angiotensin system blockers and statins are associated with lower in-hospital mortality in very elderly hypertensives. J Am Med Dir Assoc 19(4):342–347. https://doi.org/10.1016/j.jamda.2017.09.023CrossRefPubMed

Shen L et al (2009) Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 31(5):500–506. https://doi.org/10.1097/SHK.0b013e318189017aCrossRefPubMed

Imai Y et al (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047):112–116. https://doi.org/10.1038/nature03712CrossRefPubMedPubMedCentral

Santos RAS et al (2019) The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol 316(5):H958–H970. https://doi.org/10.1152/ajpheart.00723.2018CrossRefPubMedPubMedCentral

Zhang P et al (2020) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized With COVID-19. Circ Res. https://doi.org/10.1161/CIRCRESAHA.120.317134CrossRefPubMedPubMedCentral

Meng J et al (2020) Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9(1):757–760. https://doi.org/10.1080/22221751.2020.1746200CrossRefPubMedPubMedCentral

Li J et al (2020) Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan. China JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1624CrossRefPubMed

Salehi S et al (2020) Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 14:1–7. https://doi.org/10.2214/AJR.20.23034CrossRef

Title: Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
Authors: Riccardo Sarzani
Federico Giulietti
Chiara Di Pentima
Andrea Filipponi
Francesco Spannella
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Losartan
SARS-CoV-2
Acute Respiratory Distress-Syndrome
COVID-19
Published in: Internal and Emergency Medicine / Issue 5/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02365-5

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2020

Managing anticoagulation in the COVID-19 era between lockdown and reopening phases

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies

COVID-19: counter-intuitive data on smoking prevalence and therapeutic implications for nicotine

Treat all COVID 19-positive patients, but do not forget those negative with chronic diseases

COVID-19: a clinical and organizational crisis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage